Stockscreener 앱 받기
1.73
0.58%
0.01
시간 외 거래:
1.70
-0.03
-1.73%
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
PRQR|ProQR Therapeutics NV|Price:1.720|Chg%:-0.070 - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProQR Therapeutics NV (PRQR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProQR Therapeutics N.V. Revenue Breakdown – BMV:PRQR/N - TradingView
TradingKey - TradingKey
ProQR Therapeutics NV (PRQR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProQR Therapeutics NV (PRQR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Privium Fund Management B.V. Increases Stake in ProQR Therapeuti - GuruFocus
Bart Filius Acquires Additional Shares in ProQR Therapeutics NV - GuruFocus
Form 4 ProQR Therapeutics N.V. For: 21 July By Investing.com - Investing.com South Africa
Proqr Therapeutics N.v. Insider Bought Shares Worth $257,925, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) director purchases 150,000 Ordinary Shares - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR Therapeutics (PRQR) Gains 1.8% as Shares Test Key Resistance Near $1.78Entry Point Alerts - dars.gov.et
ProQR Therapeutics N.V. SEC Filing (Jul 16, 2026) - Stock Titan
ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet - Stock Titan
Aescap group and Patrick Krol report ProQR (PRQR) shareholdings - Stock Titan
Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares - MarketBeat
ProQR (PRQR) CEO lifts stake to 300,000 shares - Stock Titan
ProQR Therapeutics (PRQR) Faces Pressure at $1.73 After 1.7% DeclineSocial Sentiment - dars.gov.et
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ProQR (PRQR) CEO Daniel de Boer purchases 150,000 Ordinary Shares at $1.59 - Stock Titan
ProQR Therapeutics files prospectus for 3.03M share offering - scanx.trade
ProQR Therapeutics (PRQR) registers 3.03M shares for resale on Nasdaq - Stock Titan
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly - MSN
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR) - Seeking Alpha
ProQR posts early-stage trial data for liver disease candidate - MSN
Insider Buying: ProQR Therapeutics Independent Non-Executive Director Bought €231k Of Shares - simplywall.st
PRQRProQR Therapeutics N.V Options - Finviz
PRQR Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineEarnings Preview - dars.gov.et
Bart Filius Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com - Investing.com South Africa
Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances - Stock Titan
ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike - Stock Titan
Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market - Stock Titan
ProQR Therapeutics N.V. Actuals & Estimates (TRADEGATE:0PQ) - TradingView
0PQ Forecast — Price Target — Prediction for 2027 - TradingView
PRQR Maintained by Evercore ISI Group -- Price Target Raised to $6.00 - GuruFocus
Small-cap ProQR Therapeutics secures funding from Eli Lilly on early trial success - MSN
ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement - The Globe and Mail
ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares - Stock Titan
PRQR Maintains Buy Rating by Jones Trading -- Price Target Lowered to $10.00 - GuruFocus
PRQR Maintained by Chardan Capital -- Price Target Lowered to $3 - GuruFocus
ProQR Therapeutics N.V. Actuals & Estimates (DUS:0PQ) - TradingView
ProQR Therapeutics N.V. Actuals & Estimates (NASDAQ:PRQR) - TradingView
Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating - marketscreener.com
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Sahm
ProQR (PRQR) prices share offering and Eli Lilly private placement - Stock Titan
Price to book forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
Price to sales forward of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics NVPhase 2 Program Expec - Moomoo
ProQR Therapeutics N.V. Actuals & Estimates (MUN:0PQ) - TradingView
PRQR Forecast — Price Target — Prediction for 2027 - TradingView
1.97%
0.83%
자본화:
|
볼륨(24시간):